Compare EFSI & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFSI | ADAG |
|---|---|---|
| Founded | 1881 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.1M | 222.2M |
| IPO Year | 1996 | 2020 |
| Metric | EFSI | ADAG |
|---|---|---|
| Price | $45.97 | $2.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $47.00 | $9.91 |
| AVG Volume (30 Days) | 38.2K | ★ 225.9K |
| Earning Date | 10-22-2026 | 08-12-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | $129.59 |
| P/E Ratio | $18.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $31.44 | $1.50 |
| 52 Week High | $48.17 | $4.85 |
| Indicator | EFSI | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 42.05 |
| Support Level | $45.07 | N/A |
| Resistance Level | $47.73 | $2.78 |
| Average True Range (ATR) | 1.11 | 0.25 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 40.09 | 31.76 |
Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.